Page last updated: 2024-09-03

gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate and Adenocarcinoma Of Kidney

gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate has been researched along with Adenocarcinoma Of Kidney in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Allegrini, PR; Drevs, J; Esser, N; Fuxius, S; Hennig, J; Hugenschmidt, H; Konerding, MA; Marmé, D; Müller-Driver, R; Unger, C; Wittig, C; Wood, J1

Other Studies

1 other study(ies) available for gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate and Adenocarcinoma Of Kidney

ArticleYear
PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.
    Cancer research, 2002, Jul-15, Volume: 62, Issue:14

    Topics: Angiogenesis Inhibitors; Animals; Benzimidazoles; Blood Vessels; Capillary Permeability; Carcinoma, Renal Cell; Enzyme Inhibitors; Extravasation of Diagnostic and Therapeutic Materials; Female; Fluorescent Dyes; Heterocyclic Compounds; Kidney Neoplasms; Magnetic Resonance Angiography; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Organometallic Compounds; Phthalazines; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Regional Blood Flow

2002